Name: SOLIGENIX INC (SNGX) Stock
Brand: SOLIGENIX INC
Rating: 4 (3 reviews)

SNGX Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Soligenix, Inc.

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

11 days ago - By: Soligenix, Inc.

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

13 days ago - By: Soligenix, Inc.

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

13 days ago - By: Soligenix, Inc.

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

12 days ago - By: BioMedWire - Mentions: AMGN FOLD CTOR TNXP

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

a month ago - By: Soligenix, Inc.

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

2 months ago - By: Stocktwits

Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally

14 days ago - By: BioMedWire - Mentions: PFE MRK BMY INSM

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

a month ago - By: Soligenix, Inc.

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

2 months ago - By: Soligenix

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

2 months ago - By: Soligenix, Inc.

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

3 months ago - By: Soligenix, Inc.

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

3 months ago - By: Soligenix, Inc.

Soligenix Announces Closing of $7.5 Million Public Offering

3 months ago - By: Benzinga - Mentions: CASI SSKN CRNX APLT ...

12 Health Care Stocks Moving In Friday's Intraday Session

3 months ago - By: Benzinga - Mentions: DRIO CLSD CRNX ORGO ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

3 months ago - By: Soligenix, Inc.

Soligenix Announces Pricing of $7.5 Million Public Offering

3 months ago - By: Soligenix, Inc.

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

3 months ago - By: Soligenix, Inc.

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

4 months ago - By: Soligenix, Inc.

SOLIGENIX INC (SNGX) Stock News

SNGX Latest News, Press Relases and Analysis

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Announces Closing of $7.5 Million Public Offering

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

Soligenix Announces Pricing of $7.5 Million Public Offering

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference